Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Pneumology-allergology, PIP number: P/0173/2023

Opinion/decision on a Paediatric investigation plan (PIP): Galafold, Migalastat hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0172/2023

Opinion/decision on a Paediatric investigation plan (PIP): Evenity, Romosozumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0171/2023

Opinion/decision on a Paediatric investigation plan (PIP): Livtencity, Maribavir, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0183/2023

Human medicines European public assessment report (EPAR): Mimpara, cinacalcet, Date of authorisation: 22/10/2004, Revision: 26, Status: Authorised

EMA/FVE info session on restrictions for the use of certain antimicrobials in animals, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 May 2024, 15:00 (CEST) to 23 May 2024, 16:00 (CEST)

List of European Union reference dates and frequency of submission of periodic safety update reports (PSURs)

Research projects conducted under the remit of the PRAC impact strategy

Pharmacovigilance: Overview

Human medicines European public assessment report (EPAR): Myocet liposomal (previously Myocet), doxorubicin, Date of authorisation: 13/07/2000, Revision: 25, Status: Authorised